key: cord-0741968-aukhpfr9
authors: Estrada, J. A. G.; Cheng, C.-Y.; Ku, S.-Y.; Hu, H.-C.; Yeh, H.-W.; Lin, Y.-C.; Chen, C.-P.; Cheng, S.-H.; Lin, I.-F.
title: An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901.
date: 2022-03-01
journal: nan
DOI: 10.1101/2022.02.26.22271364
sha: 1695aa83dea489ccf33d40050307c3150749fa29
doc_id: 741968
cord_uid: aukhpfr9

Background Rapid development and deployment of vaccine is crucial to control the continuously evolving COVID-19 pandemic. Placebo-controlled phase 3 efficacy trial is still standard for authorizing vaccines in majority of the world. However, due to lack of cases or participants in parts of the world, this has not always been feasible. An alternative to efficacy trial is immunobridging, in which the immune response or correlates of protection of a vaccine candidate is compared against an approved vaccine. Here we describe a case study where our candidate vaccine, MVC-COV1901, has been granted for emergency use authorization (EUA) locally based on the non-inferiority immunobridging process. Methods The per protocol immunogenicity (PPI) subset from the MVC-COV1901 phase 2 trial was used for this study and consisted of 903 subjects who have received two doses of MVC-COV1901 as scheduled in the clinical trial. The comparator set of population consisted of 200 subjects of [≥] 20 years of age who were generally healthy, and have received two doses of AstraZeneca ChAdOx nCOV-19 (AZD1222) recruited from Taoyuan General Hospital, Ministry of Health and Welfare. Results MVC-COV1901 was shown to have a geometric mean titer (GMT) ratio lower bound 95% confidence internal (CI) of 3.4 against the comparator vaccine and a seroconversion rate of 95.5% at the 95% CI lower bound, which both exceeded the criteria set by the Taiwan regulatory authority for EUA approval. These results supported the EUA approval of MVC-COV1901 by the Taiwanese regulatory authority in July 2021. Following the consensus of the International Coalition of Medicines Regulatory Authorities (ICMRA), countries from the Access Consortium has recently adopted the use of immunobridging studies as acceptable for authorizing COVID-19 vaccines in lieu of efficacy data. Conclusion The data presented in the study showed that it is reasonably likely that the vaccine efficacy of MVC-COV1901 is similar or superior to that of AZ. Data could be used in support of further vaccine development and regulatory approval.

Background 25

Rapid development and deployment of vaccine is crucial to control the continuously evolving 26 COVID-19 pandemic. Placebo-controlled phase 3 efficacy trial is still standard for authorizing 27 vaccines in majority of the world. However, due to lack of cases or participants in parts of the world, 28 this has not always been feasible. An alternative to efficacy trial is immunobridging, in which the 29 immune response or correlates of protection of a vaccine candidate is compared against an approved 30 vaccine. Here we describe a case study where our candidate vaccine, MVC-COV1901, has been 31 granted for emergency use authorization (EUA) locally based on the non-inferiority immunobridging 32 process. 33

The per protocol immunogenicity (PPI) subset from the MVC-COV1901 phase 2 trial was used for CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) MVC-COV1901 is a protein subunit SARS-CoV-2 vaccine based on the stabilized prefusion spike 55 protein S-2P adjuvanted with CpG 1080 [1] . From 2020 to early 2021, Taiwan has been spared from 56 the worst of the pandemic, which recorded only a total of local and imported of 525 cases in 2020 and 57 339 cases in 2021 prior to the local outbreak in May 2021 [2] . As a result, it was not feasible to conduct 58 placebo-controlled efficacy trial locally in Taiwan at the time. In response, Taiwan health authorities 59 designed a pathway to EUA for all local vaccine candidates based on immunobridging, which 60 compares the immune response of a vaccine candidate with an approved vaccine for comparison [3] . 61

Over 3,800 participants were enrolled in a phase 2 clinical trial for MVC-COV1901 and the results of 62 this large-scale phase 2 trial allowed the Taiwan regulatory authorities to examine the safety and 63 immunogenicity to the comparator vaccine which has already been approved in Taiwan is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The comparator vaccine is ChAdOxAZD1222, an adenoviral vector vaccine developed by Oxford 105 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. vaccine against a comparator vaccine which has already been approved in Taiwan. 113

• Safety data: At least 3,000 subjects were required to be tracked for at least one month for 114 safety data after the last dose and all subjects to be followed for a median of two months 115 after the last dose. 116

As the AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine was the first COVID-19 vaccine to be 117 approved in Taiwan, it was chosen as the comparator vaccine for which the locally developed vaccines 118 are to be benchmarked with [3] . The immunobridging criteria were to fulfill the following endpoints 119 for serum samples 28 days after the second dose (Day 57) in population under the age of 65 [3, 9]: 120 1. The lower limit of the 95% confidence interval of the geometric mean titer ratio (GMTR) 121 of the prototype strain live virus neutralizing antibodies for the MVC-COVID19 vaccine 122 group to the external control group must be greater than 0.67, as shown in a blood test 28 123 days after the second dose; 124 2. The sero-response level was defined as the neutralizing antibody titers against the 125 prototype strain live virus at 28 days after receiving the second dose of the vaccine, at the 126 referred point of 60% reverse accumulative distribution curve for external control group 127

The lower limit of the 95% confidence interval for the sero-response rate (the proportion of 128 subjects whose neutralizing antibody titers against the prototype strain live virus, at 28 129 days after receiving the second dose of the MVC-COVID19 vaccine are above the 130 sero-response level) must be greater than 50% 131 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. GMTs of 186 and 733, respectively (Figure 1 ). When including the above 65 years of age into the 165 GMT calculation, the GMTs decreased to 184 and 662 for the AZ and MVC groups, respectively, due 166 to the inclusion of lower neutralizing antibody titer levels in the older age group (Figure 1 ). According 167 to the analysis for immunobridging study, the results showed that the lower limit of the 95% CI for the 168 GMTR of the prototype strain live virus neutralizing antibodies between MVC and AZ groups was 3.4 169 times, which was greater than the requirement of 0.67 times. The lower limit of the 95% confidence 170 interval for the sero-response rate of the MVC group was 95.5%, which was greater than the 171 requirement of 50%. 172 Illustrated in Figure 2 are the reverse cumulative distribution (RCD) curves of neutralizing 173 antibody titers. Higher neutralizing antibody titers were observed in the MVC group. At the referred 174 point of 60% for the AZ group, participants had neutralizing antibody titers equal to or less than 199.5 175 IU/mL. This is equivalent to approximately 90% of individuals given MVC. 176

The sensitivity analyses conducted to detect the robustness of GMT results reveal that both 178 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. The regulator's consortium recommended that the study design should be non-inferiority when 204 the choice of the active comparator has demonstrated high efficacy, or superiority if the active 205 comparator has modest efficacy. AZ being a product that has modest efficacy justified the need for 206 demonstrating the superiority to gain regulatory approval. Our study tried to simulate the 207 immunogenicity comparison between MVC-COV1901 and AZ done by the regulator in Taiwan 208 through which a EUA was granted to the former vaccine. The comparative study was not done in a 209 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 1 randomized, blinded study, but an external comparison. To increase confidence from the regulator's 210 perspective, a series of sensitivity analyses were conducted. The data showed that after omitting the 211 highest 33 percent data points of neutralizing antibody titers, the results can still hold. 212

The neutralizing antibody titers were determined using World Health Organization 213 (WHO)-certified reference standards, International Unit, IU/mL. The use of the standardized unit to 214 report humoral immunogenicity could facilitate future cross-platform or cross-lab comparison. The 215 study participants of both vaccines are mainly Taiwanese, reporting in IU/mL could follow 216 cross-ethnicity comparison. 217

There are a few limitations of this study, first, the design is not randomized, double blinded, but 218 an external comparison, which will compromise the level of evidence. Second, the cell-medicated 219 immunity was not included in the comparative immunogenicity profile. Third, other characterizations 220 that are of interests, including the waning immunity of both vaccines, the cross-reactivity against 221

Variants of Concern (VoCs), were not explored. 222

The data presented in the study showed that it is reasonably likely that the vaccine efficacy of 223 MVC-COV1901 is similar or superior to that of AZ. The data could be used in support of further 224 vaccine development and regulatory approval. 225 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. * The GMT Ratio was adjusted for age, gender, BMI, and comorbidity profile using general linear models.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.26.22271364 doi: medRxiv preprint

Development of CpG-adjuvanted stable prefusion 241

SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19

Taiwan Centers for Disease Control. Taiwan National Infectious Disease Statistics System

is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.26.22271364 doi: medRxiv preprint